Oracle makes clinical trial AI agents available to early adopters
Oracle says its AI Agents for clinical trial operations are available to early adopters, with an initial focus on portfolio monitoring, trial planning and trial conduct. The agents are designed to flag operational issues and recommend responses for people to review and approve.

Key takeaways · 4
- 01
The initial release focuses on portfolio monitoring, trial planning and trial conduct.
- 02
The service is available to early adopters and is sold per trial.
- 03
People must review recommendations and approve proposed actions before execution.
- 04
Oracle says the outputs are not regulatory grade and should not be relied on for regulatory submissions or decision-making.
A coordinated view of trial operations
Oracle says the agents combine information from Oracle Life Sciences applications and supported third-party data sources.[1] They are designed to identify operational issues, recommend actions for review and approval, and coordinate responses across clinical development workflows.[1] Oracle describes their scope as spanning performance monitoring, emerging-risk identification and response coordination across the trial lifecycle.[1] The announcement also lists clinical data management, post-trial analytics, trial design and post-market workflows.[1] This positions the service as a coordination layer across activities, rather than only a trial-planning tool.[1]
Distinct roles for planning and oversight
Oracle says the Trial Planning Agent supports protocol conversion, digital-plan generation, operational planning, country and site selection, cost estimation and schedule planning.[2] The Trial Conduct Agent provides trial health summaries, overviews, KPIs, site and subject insights, and protocol-amendment recommendations.[2] The Trial Portfolio Agent summarizes insights across a portfolio and provides trial overviews, health summaries and KPIs.[2] Oracle’s release documentation also lists a Portfolio Health overview, a centralized trials list and a centralized alerts list.[3] The alerts are AI-generated notifications that provide information or flag potential issues in ongoing trials.[3]
Plans and recommendations require oversight
The cost-efficient plan aims for the lowest possible trial cost and may increase duration; the fastest plan aims to finish as quickly as possible and may increase cost.[4] The balanced plan offers a midpoint between cost and speed.[4] Separately, an agent can monitor study performance and likely causes of KPI variances, then recommend actions that follow the trial protocol.[1] Oracle says people must review recommendations and approve proposed actions before they are executed.[1]
Availability, access and limitations
Oracle says the service is available to early adopters, is sold per trial and has a maximum of 210 AI Units.[1][2] Its documentation says single sign-on lets users move between the agents and onboarded Oracle Life Sciences applications without signing in separately.[3] Users can follow links from actionable insights, recommendations or data anomalies to relevant records in source applications.[3] Oracle says the cloud service is designed and authorized solely to process non-identifiable information.[2] It also says the service’s insights and outputs are not regulatory grade and should not be relied on for regulatory submissions or decision-making.[2]
Trial teams evaluating the service should distinguish operational support from regulatory-grade analysis, and plan for human review before proposed actions are carried out. The per-trial model and stated AI-unit maximum are also points to clarify when assessing fit and cost.
Why it matters
AI training for your team
kju.ai is built for teams: daily sessions, team analytics, and rollout support for your organization.
How this developed
19 November 2026
Oracle makes clinical trial AI agents available to early adopters